GLP1Base
Menu

Regulator: U.S. Food and Drug Administration (FDA)

GLP-1 drugs and peptides in United States

In the US, the FDA decides which medicines can be sold. Semaglutide, tirzepatide, liraglutide and the new tablet orforglipron are approved for specific uses. Pharmacies can only make custom copies in narrow cases, and FDA has ended the shortage rules that used to allow copies of semaglutide and tirzepatide. Most trending peptides, like BPC-157, are not approved for anything. Bringing in unapproved drugs is usually illegal, and FDA has sent many warning letters about misleading ads and sellers.

Last verified 2026-09-29 · how we verify

Official regulator site

GLP-1 medicines

Approved GLP-1 medicines: semaglutide (Ozempic and Rybelsus/Ozempic tablets for type 2 diabetes; Wegovy for weight management, cardiovascular risk reduction and MASH, as injection and, since 22 December 2025, tablet); tirzepatide (Mounjaro for type 2 diabetes; Zepbound for weight management and obstructive sleep apnea); liraglutide (Victoza, Saxenda and generics; Saxenda to be discontinued in January 2027); dulaglutide (Trulicity); exenatide (generic only); and orforglipron (Foundayo, obesity, approved 1 April 2026). Compounded copies: the shortage that allowed them ended (tirzepatide December 2024, semaglutide February 2025). FDA reports 990 adverse event reports for compounded semaglutide and more than 730 for compounded tirzepatide as of 31 May 2026, and warns of dosing errors, salt forms and fraudulent labels. 503A pharmacies may still compound for an individual patient only where a prescriber documents a clinically significant difference from the approved product; FDA has said it does not intend to act if four or fewer prescriptions of an essentially-copy product are filled in a calendar month. Coverage: the Medicare GLP-1 Bridge (1 July 2026 to 31 December 2027, $50 copay, no Part D deductible, no low-income subsidy) covers Foundayo, Wegovy and the Zepbound KwikPen for people who meet BMI and condition criteria and get prior authorization. Price context: TrumpRx.gov, launched 5 February 2026 as a federal price directory for manufacturer direct-to-consumer offers, showed on 29 September 2026 monthly prices of $149 for the Wegovy tablet, $199 for Wegovy and Ozempic pens and $299 for Zepbound against listed prices of about $1,028 to $1,349. Pipeline: CagriSema is under FDA review (decision expected in 2026 per Novo Nordisk); retatrutide, survodutide, eloralintide, maridebart cafraglutide and mazdutide are investigational, and FDA treats sales of retatrutide as illegal. FDA says it has warned companies selling semaglutide, tirzepatide, retatrutide, survodutide or mazdutide falsely labelled 'for research purposes' or 'not for human consumption'.

Peptides

No peptide in the trending group is FDA-approved. Approved peptide medicines that share names with 'research' products are narrow: tesamorelin (Egrifta, HIV lipodystrophy), bremelanotide (Vyleesi, premenopausal HSDD), setmelanotide (Imcivree, rare genetic and hypothalamic obesity) and elamipretide (Forzinity, Barth syndrome). Compounding: a 503A pharmacy may use a bulk peptide only if it has a USP/NF monograph, is a component of an approved drug, or is on the 503A bulks list. FDA's interim policy sorts nominated substances into Category 1 (under evaluation; FDA does not intend to act if conditions are met), Category 2 (significant safety risk) and Category 3 (insufficient support). As of the 14 May 2026 list, NAD and GHK-Cu (except injectable routes) are in Category 1; kisspeptin-10 is in 503A Category 2; ipamorelin acetate is in 503B Category 2. FDA's Category 2 page (updated 22 April 2026) shows that the nominations for BPC-157, TB-500, MOTS-c, KPV, Semax, Selank, Epitalon, DSIP (emideltide), LL-37, CJC-1295, AOD-9604, Melanotan II and other peptides were withdrawn, which removed them from Category 2 but did not authorise compounding. Sermorelin acetate is a component of a previously approved drug (Geref, discontinued), so 503A pharmacies may use it as a bulk substance if the other 503A conditions are met. Advisory process: the Pharmacy Compounding Advisory Committee met on 23 and 24 July 2026 on BPC-157 (ulcerative colitis), KPV, TB-500, MOTS-c, DSIP, Semax and Epitalon. A law-firm report says it voted in favour of recommending all but DSIP (for example BPC-157, KPV and TB-500 8 to 6, Semax 8 to 5, MOTS-c 7 to 5, Epitalon 7 to 4; DSIP 6 to 7). The votes are non-binding; adding a substance to the 503A list requires FDA acceptance and notice-and-comment rulemaking, and nothing has changed legally. FDA says it will consult the committee again before the end of February 2027 on GHK-Cu, and a law-firm report adds dihexa, LL-37, PEG-MGF and Melanotan II. Retatrutide and cagrilintide cannot be compounded under federal law. Sale and 'research use only': FDA treats products sold with 'research use only' or 'not for human consumption' labels as unapproved new drugs when the website or other context shows intended human use, and it treats bacteriostatic water sold alongside as evidence of injectable use (warning letters of 31 March and 24 August 2026). Introducing an unapproved new drug into interstate commerce violates FD&C Act sections 301(d) and 505(a). Import: personal importation of unapproved drugs is generally illegal, and US Customs and Border Protection seized about 5,000 mis-declared shipments of peptides including MOTS-c, Semax and cagrilintide in Cincinnati between December 2025 and 25 March 2026. Sport: the US Anti-Doping Agency states BPC-157 is prohibited under WADA category S0 (non-approved substances) and that a therapeutic use exemption is unlikely; athletes should check every substance on the current WADA list or Global DRO. Evidence: most human evidence for the trending peptides is limited, and FDA describes little or no human safety data for several of them.

Advertising rules

Prescription drug ads (brand-name products) must be truthful and not misleading and must present fair balance of risks and benefits under FD&C Act section 502(n) and 21 CFR 202.1, including a 'major statement' of risks and, for broadcast, a brief summary or 'adequate provision' to reach the full label. The FDA Office of Prescription Drug Promotion reviews promotion. On 9 September 2025 FDA and HHS announced thousands of letters to drug makers, about 100 cease-and-desist letters and plans for rulemaking to close the 'adequate provision' pathway; a proposed rule titled 'Transparency in Direct-to-Consumer Advertising' is listed with a December 2026 target date and would, according to legal commentary citing the Unified Agenda, make TV ads much harder. It is a plan, not a rule. For compounded drugs FDA warns telehealth firms against claiming a compounded drug is 'generic', the same as or equivalent to an approved drug, FDA-approved or evaluated, clinically proven to match the approved drug, made by an 'FDA-approved' pharmacy, or branded so it looks as if the telehealth firm is the compounder (30 warning letters on 3 March 2026; guidance page updated 15 June 2026). Selling or promoting unapproved drugs, including products labelled 'research use only', is treated as marketing an unapproved new drug. The Federal Trade Commission separately requires competent and reliable scientific evidence for health and weight-loss claims in non-prescription advertising and in general marketing.

Every molecule in United States

MoleculeStatusWhat it meansVerified
AmycretinNot approvedNo FDA approval or filing; Novo Nordisk now calls it zenagamtide and has started Phase 3 trialsDetails →source2026-09-29
AOD-9604Not approvedNo FDA approval; FDA lists AOD-9604 among withdrawn nominations after noting possible serious adverse eventsDetails →source2026-09-29
BPC-157Not approvedNo FDA approval and not on the 503A list; an FDA advisory panel recommended considering it in July 2026, but that vote is not bindingDetails →source2026-09-29
Bremelanotide (PT-141)Approved, restrictedFDA-approved as Vyleesi (2019) only for low sexual desire in premenopausal women with a specific diagnosisDetails →source2026-09-29
Cagrilintide (and CagriSema)Under reviewNot approved alone; Novo Nordisk's CagriSema (cagrilintide plus semaglutide) is under FDA review for obesity, and cagrilintide cannot be compoundedDetails →source2026-09-29
CJC-1295Not approvedNo FDA approval; FDA lists CJC-1295 among withdrawn nominations and cites serious adverse events, so it is not on the 503A listDetails →source2026-09-29
DSIP (delta sleep-inducing peptide)Not approvedNo FDA approval; advisers reviewed emideltide (DSIP) in July 2026 and, per a law-firm report, did not recommend itDetails →source2026-09-29
DulaglutideApprovedFDA-approved as Trulicity for type 2 diabetes since 2014; as a biologic it cannot be compoundedDetails →source2026-09-29
EcnoglutideNot approvedNot approved in the US; only early-stage US studies of an oral form have been registeredDetails →source2026-09-29
Elamipretide (SS-31)Approved, restrictedFDA-approved under accelerated approval on 19 September 2025 as Forzinity for Barth syndrome onlyDetails →source2026-09-29
EloralintideNot approvedInvestigational; Eli Lilly is running Phase 3 obesity trials and nothing is approved or filedDetails →source2026-09-29
EpitalonNot approvedNo FDA approval; an advisory panel voted in July 2026 to recommend considering it, but the vote is not bindingDetails →source2026-09-29
ExenatideGenerics availableByetta and Bydureon BCISE are listed as discontinued; an FDA-approved generic exenatide (Amneal) is on the marketDetails →source2026-09-29
GHK-Cu (copper peptide)Compounding restrictedNot approved as a drug; FDA treats non-injectable GHK-Cu as under evaluation (Category 1) but the injectable route is not coveredDetails →source2026-09-29
IpamorelinNot approvedNo FDA approval; FDA keeps ipamorelin in Category 2 for 503B outsourcing facilities because of immunogenicity and safety concernsDetails →source2026-09-29
KisspeptinNot approvedNo FDA approval; kisspeptin-10 is in FDA's 503A Category 2 because of immunogenicity and missing safety dataDetails →source2026-09-29
KPVNot approvedNo FDA approval; FDA found no human exposure data for KPV, and an advisory panel recommended considering it in July 2026 (non-binding)Details →source2026-09-29
LiraglutideGenerics availableBrand Victoza and Saxenda plus several FDA-approved generics; liraglutide is still on FDA's shortage list and Saxenda is being discontinuedDetails →source2026-09-29
LL-37Not approvedNo FDA approval; FDA notes lab findings of possible harm to male reproduction and tumour promotion, and its advisers will look at it by February 2027Details →source2026-09-29
Maridebart cafraglutide (MariTide)Not approvedInvestigational; Amgen is running Phase 3 trials (MARITIME programme) and no FDA approval or filing has been reportedDetails →source2026-09-29
MazdutideNot approvedNot approved by FDA; Eli Lilly has run US Phase 2 studies of the medicine (LY3305677) but no application has been reportedDetails →source2026-09-29
Melanotan IINot approvedNo FDA approval; FDA cites reports of melanoma and other serious events, and its advisers will consider it before the end of February 2027Details →source2026-09-29
MOTS-cNot approvedNo FDA approval; FDA found no human exposure data, and a July 2026 advisory vote to consider it is non-bindingDetails →source2026-09-29
NAD+Compounding restrictedNo FDA-approved NAD+ drug; FDA lists NAD in Category 1 (under evaluation), which lets 503A pharmacies compound it under FDA's interim policyDetails →source2026-09-29
OrforglipronApprovedFDA-approved on 1 April 2026 as Foundayo, a tablet for obesity, or overweight with a weight-related conditionDetails →source2026-09-29
PramlintideApproved, restrictedApproved as Symlin in 2005 for mealtime insulin users with diabetes, but the maker has notified FDA it is discontinuing the productDetails →source2026-09-29
RetatrutideProhibitedNot approved; FDA says retatrutide cannot be compounded and has warned sellers, so lawful access is limited to trials and expanded accessDetails →source2026-09-29
SelankNot approvedNo FDA approval; FDA lists Selank among withdrawn nominations and it was not on the July 2026 advisory agendaDetails →source2026-09-29
SemaglutideApprovedFDA-approved as Ozempic, Rybelsus and Wegovy; compounded copies lost their shortage cover in 2025 and 503B is proposing a formal exclusionDetails →source2026-09-29
SemaxNot approvedNo FDA approval; an advisory panel voted in July 2026 to recommend considering it for the 503A list, but FDA has not actedDetails →source2026-09-29
SermorelinCompounding restrictedPreviously FDA-approved as Geref (now discontinued, not for safety reasons); sermorelin acetate can be compounded only under 503A/503B conditionsDetails →source2026-09-29
SetmelanotideApproved, restrictedFDA-approved as Imcivree (2020) for specific rare genetic or hypothalamic forms of obesity, not for general obesityDetails →source2026-09-29
SurvodutideNot approvedInvestigational; Boehringer Ingelheim has US Phase 3 trials running and no FDA approval existsDetails →source2026-09-29
TB-500 (thymosin beta-4 fragment)Not approvedNo FDA approval; FDA lists TB-500 (thymosin beta-4 fragment) as having no identified human exposure data, and a July 2026 advisory vote is non-bindingDetails →source2026-09-29
TesamorelinApproved, restrictedFDA-approved since 2010 as Egrifta only for extra belly fat in adults with HIV and lipodystrophy; not for weight lossDetails →source2026-09-29
TirzepatideApprovedFDA-approved as Mounjaro (type 2 diabetes) and Zepbound (weight management, sleep apnea); shortage over since December 2024Details →source2026-09-29

For experts

The regulatory detail

Approval. Drugs need FDA approval before marketing (NDA under FD&C Act 505; biologics under a BLA). The approved incretin and related products in this atlas are semaglutide (Ozempic, Rybelsus, Wegovy injection and tablet), tirzepatide (Mounjaro, Zepbound), liraglutide (Victoza, Saxenda and several ANDA generics), dulaglutide (Trulicity), orforglipron (Foundayo, approved 1 April 2026 for obesity), exenatide (brands discontinued; generic marketed) and pramlintide (Symlin, being discontinued). CagriSema (cagrilintide plus semaglutide) has an NDA under review; retatrutide and the other pipeline agents are unapproved. Compounding. Section 503A covers state-licensed pharmacies and physicians compounding for an identified patient; section 503B covers registered outsourcing facilities (CGMP, adverse-event reporting, office-stock allowed). 503A may use bulk drug substances only if they meet a USP/NF monograph, are components of an FDA-approved drug, or appear on the 503A bulks list; 503B may use them only if on the 503B clinical-need list or if the drug is on FDA's shortage list. Both bar routine compounding of drugs that are essentially copies of commercially available products (FDA treats a product with the same active ingredient in the same, similar or easily substitutable strength by the same route as essentially a copy, and says semaglutide plus vitamin B12 may count as one). FDA declared the tirzepatide shortage resolved on 19 December 2024 and the semaglutide shortage resolved on 21 February 2025; enforcement discretion ended in 2025 after courts denied injunctions. On 1 May 2026 FDA proposed not to include semaglutide, tirzepatide or liraglutide on the 503B bulks list (comment period extended to 30 July 2026); that proposal is not final. Liraglutide presentations are still on FDA's shortage list, and biologics such as dulaglutide cannot be compounded at all. FDA says retatrutide and cagrilintide cannot be compounded and has said it knows of no lawful basis for semaglutide salt forms. Personal importation. FDA says it is illegal in most circumstances to import drugs for personal use; case-by-case discretion is narrow (serious condition, no domestic alternative, three-month supply, written personal-use affirmation). FDA also runs a green-list import alert (66-80) for GLP-1 active ingredients of concern. Coverage and pricing. CMS runs a temporary Medicare GLP-1 Bridge demonstration from 1 July 2026 to 31 December 2027, outside the normal Part D benefit and payment flow, with a $50 copay for eligible people using Foundayo, Wegovy or the Zepbound KwikPen. The federal TrumpRx.gov site lists reduced cash prices for several GLP-1 brands. Recent enforcement. FDA sent 30 warning letters to telehealth firms on 3 March 2026 over sameness and sourcing claims for compounded GLP-1s (thousands of advertising letters since September 2025), and CDER issued warning letters in 2026 to online sellers of unapproved retatrutide, semaglutide and peptides with 'research use only' labels. US customs seized about 5,000 shipments of mis-declared peptides in Cincinnati between December 2025 and March 2026.

Official sources we monitor

Recent changes in United States

  1. 2026-08-28

    FDA approves Mounjaro to lower cardiovascular risk in adults with type 2 diabetes

    Eli Lilly announced on 28 August 2026 that the FDA approved Mounjaro to lower the risk of major cardiovascular events in adults with type 2 diabetes at high risk. The approval was based on SURPASS-CVOT, which compared tirzepatide with dulaglutide and showed non-inferiority.

  2. 2026-08-27

    Fifth Circuit upholds the FDA's tirzepatide shortage decision

    On 27 August 2026 the US Court of Appeals for the Fifth Circuit affirmed the lower court's ruling in Outsourcing Facilities Association v. FDA (No. 25-10600). It held that the FDA's decision to remove tirzepatide from its shortage list did not violate the Administrative Procedure Act, either for lack of notice-and-comment rulemaking or as arbitrary and capricious. The opinion is not designated for publication.

  3. 2026-08-24

    FDA sends more warning letters to online peptide sellers

    The FDA issued further warning letters to online peptide sellers dated 24 August 2026. One letter said 'research use only' and 'not for human consumption' labels did not change that website evidence showed the products were intended to be drugs for human use. These are the FDA's stated positions, not court findings.

  4. 2026-08-12

    Lilly files six lawsuits over unapproved retatrutide products

    On 12 August 2026 Eli Lilly said it had filed six new lawsuits against US entities including compounding pharmacies, medical spas and online sellers over products marketed as retatrutide, which is not approved anywhere. Lilly said it had reported more than 14,000 websites, advertisements, social media posts and product listings and referred more than 200 parties to authorities. The allegations are Lilly's and had not been decided by a court at the time of the announcement.

  5. 2026-07-30

    Owner of Paradigm Peptides sentenced to 70 months in prison

    On 30 July 2026 the US Attorney's Office for the Northern District of Indiana announced that the owner of Paradigm Peptides had been sentenced to 70 months in prison and his sister to 16 months, after each pleaded guilty to introducing unapproved new drugs into interstate commerce with intent to defraud and mislead. The office said the business sold peptides and other drugs for human consumption without FDA approval; the owner also pleaded guilty to illegally importing merchandise.

  6. 2026-07-23

    FDA advisory committee votes on seven peptides for the 503A compounding list, against FDA staff advice

    At a two-day Pharmacy Compounding Advisory Committee meeting on 23 and 24 July 2026, the panel voted to recommend BPC-157, KPV and TB-500 (each 8-6), MOTS-c, epitalon and semax for the 503A bulks list, but not emideltide (DSIP), according to a law-firm summary. It reports that FDA scientists recommended against inclusion in each case. The votes are advice only: adding a peptide requires FDA notice-and-comment rulemaking, and the votes do not make any of these peptides an approved medicine.

  7. 2026-07-21

    Novo Nordisk sues Eli Lilly over GLP-1 advertising

    On 21 July 2026 Novo Nordisk filed a lawsuit against Eli Lilly in federal court in New Jersey, according to CNBC. Novo alleges false advertising and unfair competition, including under the Lanham Act, in Lilly's advertising for its obesity and diabetes medicines such as Zepbound. Lilly said it stands firmly behind its advertising. These are allegations that no court had ruled on at the time of the report.

  8. 2026-07-01

    Medicare GLP-1 Bridge set to start, with a $50 co-pay for eligible weight-management prescriptions

    CMS's Medicare GLP-1 Bridge, a short-term demonstration, was set to give eligible Part D beneficiaries access to certain GLP-1 drugs for weight management at a $50 co-pay from 1 July 2026, outside the normal Part D benefit. CMS lists Wegovy (injection and tablets), Foundayo and Zepbound (KwikPen) as eligible. In April 2026 CMS extended the Bridge to run through 31 December 2027.

  9. 2026-04-30

    FDA proposes to bar bulk compounding of semaglutide, tirzepatide and liraglutide by outsourcing facilities

    On 30 April 2026 the FDA proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list, saying it found no clinical need for outsourcing facilities to compound them from bulk substances. The FDA invited comments until 29 June 2026 and said it would consider them before making a final determination.

  10. 2026-04-21

    CMS delays the Medicare part of the BALANCE model and extends the GLP-1 Bridge through 2027

    On 21 April 2026 CMS announced it would not implement the BALANCE model in Medicare Part D in 2027 and would instead extend the temporary Medicare GLP-1 Bridge to the end of 2027. The Medicaid part of BALANCE, which state Medicaid programmes can join, continues.

Full timeline →

Sources (64)

  1. 01FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight LossU.S. Food and Drug Administration · 2026-09-01 · accessed 2026-09-29
  2. 02FDA clarifies policies for compounders as national GLP-1 supply begins to stabilizeU.S. Food and Drug Administration · 2026-04-01 · accessed 2026-09-29
  3. 03List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B (proposal not to include semaglutide, tirzepatide, liraglutide)Federal Register (FDA) · 2026-05-01 · accessed 2026-09-29
  4. 04List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B; Extension of Comment PeriodFederal Register (FDA) · 2026-06-26 · accessed 2026-09-29
  5. 05Bulk Drug Substances Used in CompoundingU.S. Food and Drug Administration · 2026-03-26 · accessed 2026-09-29
  6. 06Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C ActU.S. Food and Drug Administration · 2026-05-14 · accessed 2026-09-29
  7. 07Bulk Drug Substances Nominated for Use in Compounding Under Section 503A (Categories 1, 2 and 3)U.S. Food and Drug Administration · 2026-05-14 · accessed 2026-09-29
  8. 08Bulk Drug Substances Nominated for Use in Compounding Under Section 503B (Categories 1, 2 and 3)U.S. Food and Drug Administration · 2025-03-21 · accessed 2026-09-29
  9. 09Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (Category 2 and withdrawn nominations)U.S. Food and Drug Administration · 2026-04-22 · accessed 2026-09-29
  10. 10July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory CommitteeU.S. Food and Drug Administration · 2026-08-06 · accessed 2026-09-29
  11. 11Bulk list bound? PCAC backs majority of peptides in two-day public meetingMcDermott Will & Schulte · 2026-07-27 · accessed 2026-09-29
  12. 12FDA's Advisory Committee Votes on Peptides: What It Does and Does Not MeanMintz · 2026-07-29 · accessed 2026-09-29
  13. 13Compounding and the FDA: Questions and AnswersU.S. Food and Drug Administration · 2025-09-16 · accessed 2026-09-29
  14. 14Personal ImportationU.S. Food and Drug Administration · 2025-08-18 · accessed 2026-09-29
  15. 15Cincinnati CBP foils scheme to smuggle over 5,000 unapproved peptides into the U.S.U.S. Customs and Border Protection · 2026-03-31 · accessed 2026-09-29
  16. 16FDA warning letter 721806 to an online seller of retatrutide, tirzepatide and bacteriostatic water labelled 'research use only'U.S. Food and Drug Administration · 2026-03-31 · accessed 2026-09-29
  17. 17FDA warning letter 735127 to an online seller of retatrutide, semaglutide, SS-31, PT-141 and tesamorelin labelled 'research use only'U.S. Food and Drug Administration · 2026-08-24 · accessed 2026-09-29
  18. 18FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1sU.S. Food and Drug Administration · 2026-03-03 · accessed 2026-09-29
  19. 19FDA to Telehealth Companies: What to Know When Promoting Compounded DrugsU.S. Food and Drug Administration · 2026-06-15 · accessed 2026-09-29
  20. 20FDA Launches Crackdown on Deceptive Drug AdvertisingU.S. Food and Drug Administration · 2025-09-09 · accessed 2026-09-29
  21. 2121 CFR 202.1 Prescription-drug advertisementsLegal Information Institute, Cornell Law School (Code of Federal Regulations) · 2026 · accessed 2026-09-29
  22. 22Coming soon: proposed rule to remove 'adequate provision' and ban DTC TV adsFDA Law Blog (Hyman, Phelps & McNamara) · 2026-07-07 · accessed 2026-09-29
  23. 23Health Products Compliance GuidanceFederal Trade Commission · 2022-12 · accessed 2026-09-29
  24. 24Medicare GLP-1 BridgeCenters for Medicare & Medicaid Services · 2026-07-13 · accessed 2026-09-29
  25. 25Medicare GLP-1 Bridge: who is eligible and which drugs are coveredMedicare.gov (CMS) · 2026 · accessed 2026-09-29
  26. 26Fact Sheet: President Donald J. Trump Launches TrumpRx.gov to Bring Lower Drug Prices to American PatientsThe White House · 2026-02-05 · accessed 2026-09-29
  27. 27TrumpRx.gov home page (price cards observed 2026-09-29)TrumpRx.gov (U.S. federal government) · 2026-09-29 · accessed 2026-09-29
  28. 28BPC-157: What Athletes Should Know About the Prohibited Experimental PeptideU.S. Anti-Doping Agency · 2026-08-10 · accessed 2026-09-29
  29. 29Novo Nordisk financial report for 2025 (Form 6-K, company announcement)Novo Nordisk A/S (SEC filing) · 2026-02-03 · accessed 2026-09-29
  30. 30Novo Nordisk financial report for the period 1 January to 30 June 2026 (Form 6-K)Novo Nordisk A/S (SEC filing) · 2026-08-04 · accessed 2026-09-29
  31. 31Development & Approval Process | DrugsU.S. Food and Drug Administration · 2022-08-08 · accessed 2026-09-29
  32. 32VYLEESI (bremelanotide) injection prescribing informationU.S. Food and Drug Administration · 2020-10 · accessed 2026-09-29
  33. 33TRULICITY (dulaglutide) injection prescribing informationU.S. Food and Drug Administration · 2026-03 · accessed 2026-09-29
  34. 34A Study of Weekly Oral Ecnoglutide (VRB-101) in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities, NCT07281937U.S. National Library of Medicine (ClinicalTrials.gov) · 2026-08 · accessed 2026-09-29
  35. 35FORZINITY (elamipretide) prescribing information (original approval)U.S. Food and Drug Administration · 2025-09 · accessed 2026-09-29
  36. 36A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight Without Type 2 Diabetes, NCT07321886U.S. National Library of Medicine (ClinicalTrials.gov) · 2026-09 · accessed 2026-09-29
  37. 37Eli Lilly and Company Form 10-Q for the quarter ended 30 June 2026Eli Lilly and Company (SEC filing) · 2026-08-05 · accessed 2026-09-29
  38. 38BYETTA (exenatide) injection prescribing informationU.S. Food and Drug Administration · 2025-06 · accessed 2026-09-29
  39. 39BYDUREON BCISE (exenatide extended-release) prescribing informationU.S. Food and Drug Administration · 2025-06 · accessed 2026-09-29
  40. 40Drugs@FDA data via openFDA: exenatide applications (Byetta, Bydureon, generic)U.S. Food and Drug Administration · 2026-09-24 · accessed 2026-09-29
  41. 41VICTOZA (liraglutide) injection prescribing informationU.S. Food and Drug Administration · 2025-10 · accessed 2026-09-29
  42. 42SAXENDA (liraglutide) injection prescribing informationU.S. Food and Drug Administration · 2026-03 · accessed 2026-09-29
  43. 43Drugs@FDA data via openFDA: liraglutide applications (brands and generics)U.S. Food and Drug Administration · 2026-09-24 · accessed 2026-09-29
  44. 44FDA Drug Shortages data via openFDA: liraglutide injectionU.S. Food and Drug Administration · 2026-09-22 · accessed 2026-09-29
  45. 45Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity, NCT07037433U.S. National Library of Medicine (ClinicalTrials.gov) · 2026-09 · accessed 2026-09-29
  46. 46A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight, NCT06124807U.S. National Library of Medicine (ClinicalTrials.gov) · 2026-04 · accessed 2026-09-29
  47. 47FOUNDAYO (orforglipron) tablets prescribing information (original approval)U.S. Food and Drug Administration · 2026-04 · accessed 2026-09-29
  48. 48SYMLIN (pramlintide acetate) injection prescribing informationU.S. Food and Drug Administration · 2019-12 · accessed 2026-09-29
  49. 49Drugs@FDA data via openFDA: pramlintide application (Symlin, marketing status)U.S. Food and Drug Administration · 2026-09-24 · accessed 2026-09-29
  50. 50FDA Drug Shortages data via openFDA: pramlintide acetate injection (to be discontinued)U.S. Food and Drug Administration · 2025-10-27 · accessed 2026-09-29
  51. 51Pre-approval Expanded Access of Retatrutide (LY3437943), NCT07629401U.S. National Library of Medicine (ClinicalTrials.gov) · 2026-08 · accessed 2026-09-29
  52. 52A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight, NCT05929066U.S. National Library of Medicine (ClinicalTrials.gov) · 2026-08 · accessed 2026-09-29
  53. 53OZEMPIC (semaglutide) injection prescribing informationU.S. Food and Drug Administration · 2026-05 · accessed 2026-09-29
  54. 54RYBELSUS / OZEMPIC (semaglutide) tablets prescribing informationU.S. Food and Drug Administration · 2026-07 · accessed 2026-09-29
  55. 55WEGOVY (semaglutide) injection and tablets prescribing informationU.S. Food and Drug Administration · 2026-09 · accessed 2026-09-29
  56. 56Novo Nordisk announcement: FDA approves the Wegovy pill (Form 6-K)Novo Nordisk A/S (SEC filing) · 2025-12-22 · accessed 2026-09-29
  57. 57Drugs@FDA data via openFDA: GEREF (sermorelin acetate) applications, marketing statusU.S. Food and Drug Administration · 2026-09-24 · accessed 2026-09-29
  58. 58Determination That GEREF (Sermorelin Acetate) Injection Was Not Withdrawn From Sale for Reasons of Safety or EffectivenessFederal Register (FDA) · 2013-03-04 · accessed 2026-09-29
  59. 59IMCIVREE (setmelanotide) injection prescribing informationU.S. Food and Drug Administration · 2026-03 · accessed 2026-09-29
  60. 60LIVERAGE: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis, NCT06632444U.S. National Library of Medicine (ClinicalTrials.gov) · 2026-09 · accessed 2026-09-29
  61. 61A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With NASH to Reduce Liver Fat and to Lose Weight (SYNCHRONIZE-MASLD), NCT06309992U.S. National Library of Medicine (ClinicalTrials.gov) · 2026-04 · accessed 2026-09-29
  62. 62EGRIFTA (tesamorelin) prescribing informationU.S. Food and Drug Administration · 2025-03 · accessed 2026-09-29
  63. 63MOUNJARO (tirzepatide) injection prescribing informationU.S. Food and Drug Administration · 2026-09 · accessed 2026-09-29
  64. 64ZEPBOUND (tirzepatide) injection prescribing informationU.S. Food and Drug Administration · 2026-09 · accessed 2026-09-29